Femasys Inc. (FEMY) NASDAQ
0.41
+0.0083(+2.08%)
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
0.41
+0.0083(+2.08%)
Currency In USD
| Previous Close | 0.4 |
| Open | 0.4 |
| Day High | 0.42 |
| Day Low | 0.4 |
| 52-Week High | 1.22 |
| 52-Week Low | 0.31 |
| Volume | 171,944 |
| Average Volume | 527,065 |
| Market Cap | 11.99M |
| PE | -0.87 |
| EPS | -0.47 |
| Moving Average 50 Days | 0.49 |
| Moving Average 200 Days | 0.63 |
| Change | 0.01 |
Femasys Advances FemBloc Toward U.S. Approval with Initiation of Pivotal Trial Enrollment
GlobeNewswire Inc.
Mar 10, 2026 1:00 PM GMT
-- Enrollment begins in the FDA-authorized FINALE pivotal trial evaluating FemBloc, a first-of-its-kind non-surgical permanent birth control, following positive clinical data -- ATLANTA, March 10, 2026 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY
Femasys Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire Inc.
Feb 27, 2026 10:26 PM GMT
ATLANTA, Feb. 27, 2026 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a leading biomedical innovator making fertility and non-surgical permanent birth control more accessible and cost-effective to women worldwide, announced today it has granted t
Femasys Announces FemBloc® Permanent Birth Control Has Achieved MDSAP Certification, Advancing Global Market Access
GlobeNewswire Inc.
Feb 26, 2026 2:00 PM GMT
-- FemBloc becomes the latest Femasys product to achieve MDSAP certification, building on a proven track record of compliance -- ATLANTA, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a leading biomedical innovator making fertility